Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.

89th Legislature (2025) Introduced by Daniel Alders and 33 co-sponsors

Texas would fund FDA drug trials for ibogaine addiction treatment, attempting to accelerate a controlled substance's federal approval through state-level grant investment.

Laid on the table subject to call

#alcoholism&drugabuse(i0030) #crimes--drugs(i0185) #health&humanservicescommission(v0177) #health--general(i0385) #medicine&prescriptiondrugs(s7338) #research&development(s0135) #statefinances--appropriations(i0746)

Legislative bill overview

HB 3717 would establish a Texas state grant program to fund FDA drug development trials specifically for ibogaine, a psychoactive compound, as a potential treatment for opioid use disorder and other neurological/mental health conditions. The bill aims to accelerate FDA approval pathways for ibogaine by providing state-level financial support to clinical research efforts.

Why is this important

Opioid use disorder remains a significant public health crisis, and ibogaine has shown promise in some research as an addiction treatment, though rigorous FDA approval has not been achieved. However, this represents an unusual state-level intervention in federal drug approval processes, raising questions about how Texas funding would interface with FDA requirements and whether it represents sound public health investment compared to other addiction treatment options.

Potential points of contention

Unproven efficacy: While ibogaine shows potential, it lacks robust clinical evidence and FDA approval; funding trials for an unproven substance diverts resources from established treatments

State vs. federal authority: Texas funding FDA trials creates unclear jurisdictional boundaries—the FDA controls drug approval, not state legislatures, potentially creating implementation complications

Safety concerns: Ibogaine carries cardiac and neurological risks documented in medical literature; funding its development without established safety protocols raises public health questions

Cost-benefit analysis: The bill doesn't specify funding amounts or explain why ibogaine research is prioritized over other promising addiction treatments with stronger existing evidence bases